Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) shares reached a new 52-week low on Thursday . The company traded as low as $16.10 and last traded at $16.34, with a volume of 470590 shares traded. The stock had previously closed at $18.15.
Wall Street Analyst Weigh In
BCAX has been the subject of a number of analyst reports. Stifel Nicolaus assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating and a $47.00 price target for the company. Rodman & Renshaw began coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price target for the company. HC Wainwright initiated coverage on Bicara Therapeutics in a research report on Friday, December 6th. They issued a "buy" rating and a $42.00 price target for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Finally, Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics has an average rating of "Buy" and an average target price of $43.00.
Check Out Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Stock Performance
The business's 50-day moving average price is $20.85.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). On average, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Cinctive Capital Management LP purchased a new stake in Bicara Therapeutics in the 3rd quarter worth about $229,000. Barclays PLC bought a new position in Bicara Therapeutics in the 3rd quarter worth approximately $255,000. Jane Street Group LLC purchased a new position in Bicara Therapeutics in the 3rd quarter valued at approximately $309,000. Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics during the 3rd quarter valued at $358,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Bicara Therapeutics during the third quarter worth $462,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
